Breast Cancer | Current Treatment: Physician Insights | US | 2025

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line treatments for metastatic HR-positive / HER2-negative disease; this drug class moved to the early-stage setting with the approval of adjuvant Verzenio in 2021. Biomarker-driven therapies—including Menarini Group’s Orserdu (ESR1-mutant), Novartis’s Piqray (PIK3CA-mutant), and AstraZeneca’s Truqap (PIK3CA/AKT1/PTEN-mutant)—have expanded treatment options for metastatic HR-positive / HER2-negative disease. Meanwhile, Merck & Co.’s Keytruda has changed the treatment paradigm for certain patients with early and metastatic triple-negative breast cancer. PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza, Pfizer’s Talzenna) are an option for PARP-mutant patients with either triple-negative or HR-positive / HER2-negative disease; for these two subtypes, the approval of next-generation ADCs (Gilead’s Trodelvy, Daiichi Sankyo / AstraZeneca’s Enhertu for HER2-low) has diversified therapy options for metastatic patients. In the HER2-positive metastatic setting, Enhertu´s label expansion to the second line is redefining treatment.

QUESTIONS ANSWERED

• What are the treatment rates for breast cancer by key subtype and line of therapy?
• What are physician-reported testing rates for select biomarkers (e.g., mutations in PIK3CA, ESR1, and PARP; HER2-low and PD-L1 expression) in relevant breast cancer subtypes?
• What is the patient share of key drugs and regimens by type of breast cancer?
• What are the main drivers of and key obstacles to the uptake of select therapies?

PRODUCT DESCRIPTION

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.

Primary research: Survey of 100 medical oncologists in the United States fielded in December 2024.

Key drugs: IIbrance, Kisqali, Verzenio, Lynparza, Talzenna, Piqray, Enhertu, Orserdu, Truqap, Trodelvy, Phesgo.